| Factor Information | |
|---|---|
| Data ID | 1539 |
| Factor | ECG parameters--QRS duration (ms) |
| Description | baseline data for Group A, stratified by gender. |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To examine the number of ACHD patients treated with antidepressant drugs (ADDs) at a tertiary centre, identify predictors of ADD use and test the hypothesis that severe depression requiring ADD therapy is directly or indirectly related to a worse outcome in this growing population. |
| p Value | 0.001 |
| Conclusion | baseline data for Group A, stratified by gender. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 538 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/AVSD/CoA/TOF/TGA/ccTGA/EA/ES/other |
| Reference | |
|---|---|
| PMID | 26314687 |
| Year | 2016 |
| Title | Depression requiring anti-depressant drug therapy in adult congenital heart disease: prevalence, risk factors, and prognostic value. |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | a retrospective study | |
| Region | London, UK | |
| Method | The entire ACHD cohort under active follow-up at the Royal Brompton Hospital between 2000 and 2011 was identified based on an electronic database search and was included in the analysis. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | ADD therapy | |
| Group | Group A: patients on antidepressant drugs, ADDs(males)(Treatment) | Group A: patients on antidepressant drugs, ADDs(females)(Control) |
| Number | 68 | 136 |
| Age | 34.8±15.2 years | 36.8±15.7 years |
| Gender (Male: Female) | 68:0 | 0:136 |
| Marker Level | 141 [104–165] | 103 [91–140] |
